Outcomes and prognosis in advanced renal cell carcinoma

References

• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356, 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Hudes GR, Carducci M, Tomczak P et al. A Phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-α (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. 24, 18S (2006) (Abstract LBA4).
   Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon-a in metastatic renal-cell carcinoma. N. Engl. J. Med.356, 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Zisman A, Pantuck AJ, Dorey F et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol.19, 1649–1657 (2001).
   PubMed Web of Science ®Google Scholar
• Han KR, Bleumer I, Pantuck AJ et al. Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. J. Urol.170, 2221–2224 (2003).
   Google Scholar
• Patard JJ, Kim HL, Lam JS et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J. Clin. Oncol.22, 3316–3322 (2004).
   PubMed Web of Science ®Google Scholar
• Zisman A, Pantuck AJ, Wieder J et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J. Clin. Oncol.20, 4559–4566 (2002).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol.17, 2530–2540 (1999).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Murphy BA et al. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol.20, 289–296 (2002).
   PubMed Web of Science ®Google Scholar
• Mekhail TM, Abou-Jawde RM, Boumerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol.23, 832–841 (2005).
   PubMed Web of Science ®Google Scholar
• Negrier S, Escudier B, Gomez F et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’Immunotherapie. Ann. Oncol.13, 1460–1468 (2002).
   PubMed Web of Science ®Google Scholar
• Bukowski RM, Negrier S, Elson P. Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group. Clin. Cancer Res.10, S6310–S6314 (2004).
   Google Scholar
• Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J. Clin. Oncol.22, 454–463 (2004).
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N. Engl. J. Med.345, 1655–1659 (2001).
   PubMed Web of Science ®Google Scholar
• Schwartz LH, Mazumdar M, Wang L et al. Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials. Cancer98, 1611–1619 (2003).
   PubMedGoogle Scholar
• Kovacs G, Akhtar M, Beckwith BJ et al. The Heidelberg classification of renal cell tumours. J. Pathol.183, 131–133 (1997).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Mariani T et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J. Clin. Oncol.20, 2376–2381 (2002).
   PubMed Web of Science ®Google Scholar
• Patard JJ, Leray E, Rioux-Leclercq N et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J. Clin. Oncol.23, 2763–2771 (2005).
   PubMed Web of Science ®Google Scholar
• Cohen HT, McGovern FJ. Renal-cell carcinoma. N. Engl. J. Med.353, 2477–2490 (2005).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24, 16–24 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA295, 2516–2524 (2006).
   PubMed Web of Science ®Google Scholar
• Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol.22, 909–918 (2004).
   PubMed Web of Science ®Google Scholar
• Aaltomaa S, Lipponen P, Ala-Opas M et al. Prognostic value of Ki-67 expression in renal cell carcinomas. Eur. Urol.31, 350–355 (1997).
   Google Scholar
• Sejima T, Miyagawa I. Expression of bcl-2, p53 oncoprotein, and proliferating cell nuclear antigen in renal cell carcinoma. Eur. Urol.35, 242–248 (1999).
   PubMed Web of Science ®Google Scholar
• Yasunaga Y, Shin M, Miki T et al. Prognostic factors of renal cell carcinoma: a multivariate analysis. J. Surg. Oncol.68, 11–18 (1998).
   Google Scholar
• Opavsky R, Pastorekova S, Zelnik V et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics33, 480–487 (1996).
   PubMed Web of Science ®Google Scholar
• Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res.9, 802–811 (2003).
   PubMed Web of Science ®Google Scholar
• Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res.11, 3714–3721 (2005).
   PubMed Web of Science ®Google Scholar
• Thompson RH, Kuntz SM, Leibovich BC et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res.66, 3381–3385 (2006).
   PubMed Web of Science ®Google Scholar
• Hirano F, Kaneko K, Tamura H et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res.65, 1089–1096 (2005).
   PubMed Web of Science ®Google Scholar
• Kim HL, Seligson D, Liu X et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin. Cancer Res.10, 5464–5471 (2004).
   PubMed Web of Science ®Google Scholar
• Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res.48, 7310–7313 (1988).
   PubMed Web of Science ®Google Scholar
• de Forges A, Rey A, Klink M et al. Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis. Semin. Surg. Oncol.4, 149–154 (1988).
   PubMed Web of Science ®Google Scholar
• Palmer PA, Vinke J, Philip T et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann. Oncol.3, 475–480 (1992).
   PubMed Web of Science ®Google Scholar
• Fossa SD, Kramar A, Droz JP. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-α. Eur. J. Cancer30A, 1310–1314 (1994).
   PubMedGoogle Scholar
• Atzpodien J, Royston P, Wandert T et al. Metastatic renal carcinoma comprehensive prognostic system. Br. J. Cancer88, 348–353 (2003).
   PubMed Web of Science ®Google Scholar
• Leibovich BC, Cheville JC, Lohse CM et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J. Urol.174, 1759–1763 (2005).
   PubMed Web of Science ®Google Scholar